Cognitive Impairment Associated with Cancer: A Brief Review

Overview

Journal Innov Clin Neurosci

Date 2018 Mar 3

PMID 29497579

Citations 103

Authors

J Cara Pendergrass

Steven D Targum

John E Harrison

Affiliations

Soon will be listed here.

Abstract

This brief review explores the areas of cognitive impairment that have been observed in cancer patients and survivors, the cognitive assessment tools used, and the management of the observed cognitive changes. Cognitive changes and impairment observed in patients with cancer and those in remission can be related to the direct effects of cancer itself, nonspecific factors or comorbid conditions that are independent of the actual disease, and/or the treatments or combination of treatments administered. Attention, memory, and executive functioning are the most frequently identified cognitive domains impacted by cancer. However, the prevalence and extent of impairment remains largely unknown due to marked differences in methodology, definitions of cognitive impairment, and the assessment measures used. Assessment of cognitive functioning is an important and necessary part of a comprehensive oncological care plan. Research is needed to establish a better understanding of cognitive changes and impairments associated with cancer so that optimal patient outcomes can be achieved.

Citing Articles

Longitudinal study of cognitive and mental functions among adult Hodgkin-lymphoma survivors, based on data from a primary treatment center in Hungary.

Virga I, Kosa K, Illes A, Miltenyi Z, Ivanka T, Berecz R Front Oncol. 2025; 15:1509424.

PMID: 40034597 PMC: 11872912. DOI: 10.3389/fonc.2025.1509424.

Unveiling Cognitive Impairment in Older Adults with Cancer on Systemic Anticancer Therapy: A Comprehensive Review.

Paramo Fernandez R, Fargas Baella G, Slavova-Boneva V, Battisti N Drugs Aging. 2025; .

PMID: 39976815 DOI: 10.1007/s40266-025-01186-5.

Practitioners' perspective: a mixed-methods study on dealing with suicidality from the perspective of oncological healthcare professionals.

Schwinn T, Hirschmiller J, Wiltink J, Zwerenz R, Brahler E, Beutel M J Cancer Res Clin Oncol. 2025; 151(2):54.

PMID: 39875636 PMC: 11775075. DOI: 10.1007/s00432-025-06106-z.

eHealth, digital information and technology use of men with prostate cancer.

Jackson S, Yu P, Sowter S, Occhipinti S, Chambers S, Leslie S Digit Health. 2025; 11():20552076241309214.

PMID: 39801580 PMC: 11719434. DOI: 10.1177/20552076241309214.

Exercise as a Therapeutic Strategy to Improve Cerebrovascular Function and Cognition in Breast Cancer Survivors: A Scoping Review.

Downs T, Whiteside E, Denham J, Mills D, Bliss E J Clin Med. 2025; 13(24).

PMID: 39768764 PMC: 11678850. DOI: 10.3390/jcm13247841.

References

Kesler S, Bennett F, Mahaffey M, Spiegel D . Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res. 2009; 15(21):6665-73. PMC: 2859687. DOI: 10.1158/1078-0432.CCR-09-1227. View

Ahles T, Saykin A . Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007; 7(3):192-201. PMC: 3329763. DOI: 10.1038/nrc2073. View

Verstappen C, Heimans J, Hoekman K, Postma T . Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003; 63(15):1549-63. DOI: 10.2165/00003495-200363150-00003. View

Boykoff N, Moieni M, Subramanian S . Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009; 3(4):223-32. PMC: 2775113. DOI: 10.1007/s11764-009-0098-x. View

Gehring K, Patwardhan S, Collins R, Groves M, Etzel C, Meyers C . A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol. 2011; 107(1):165-74. DOI: 10.1007/s11060-011-0723-1. View

Weijl N, Elsendoorn T, Moison R, Lentjes E, Brand R, Berger H . Non-protein bound iron release during chemotherapy in cancer patients. Clin Sci (Lond). 2003; 106(5):475-84. DOI: 10.1042/CS20030271. View

Chan R, McCarthy A, Devenish J, Sullivan K, Chan A . Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Eur J Cancer. 2015; 51(4):437-450. DOI: 10.1016/j.ejca.2014.12.017. View

McDonald B, Conroy S, Ahles T, West J, Saykin A . Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol. 2012; 30(20):2500-8. PMC: 3397784. DOI: 10.1200/JCO.2011.38.5674. View

Lageman S, Cerhan J, Locke D, Anderson S, Wu W, Brown P . Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials. J Neurooncol. 2009; 96(2):271-6. DOI: 10.1007/s11060-009-9960-y. View

10.

Meyers C, Albitar M, Estey E . Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005; 104(4):788-93. DOI: 10.1002/cncr.21234. View

11.

Sul J, DeAngelis L . Neurologic complications of cancer chemotherapy. Semin Oncol. 2006; 33(3):324-32. DOI: 10.1053/j.seminoncol.2006.03.006. View

12.

Hosseini S, Koovakkattu D, Kesler S . Altered small-world properties of gray matter networks in breast cancer. BMC Neurol. 2012; 12:28. PMC: 3404945. DOI: 10.1186/1471-2377-12-28. View

13.

Brown P, Ballman K, Rummans T, Maurer M, Sloan J, Boeve B . Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol. 2005; 76(3):283-91. DOI: 10.1007/s11060-005-7020-9. View

14.

Harrison J, Minassian S, Jenkins L, Black R, Koller M, Grundman M . A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007; 64(9):1323-9. DOI: 10.1001/archneur.64.9.1323. View

15.

Sands S, Harel B, Savone M, Kelly K, Vijayanathan V, Greene Welch J . Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Support Care Cancer. 2016; 25(2):449-457. PMC: 5580925. DOI: 10.1007/s00520-016-3422-9. View

16.

Osoba D, Brada M, PRADOS M, Yung W . Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro Oncol. 2001; 2(4):221-8. PMC: 1920595. DOI: 10.1093/neuonc/2.4.221. View

17.

van Nieuwenhuizen D, Klein M, Stalpers L, Leenstra S, Heimans J, Reijneveld J . Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. J Neurooncol. 2007; 84(3):271-8. DOI: 10.1007/s11060-007-9366-7. View

18.

Goode E, Ulrich C, Potter J . Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1513-30. View

19.

McDonald B, Conroy S, Ahles T, West J, Saykin A . Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010; 123(3):819-28. PMC: 3661415. DOI: 10.1007/s10549-010-1088-4. View

20.

Klein M, Taphoorn M, Heimans J, VAN DER Ploeg H, Vandertop W, Smit E . Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol. 2001; 19(20):4037-47. DOI: 10.1200/JCO.2001.19.20.4037. View